Misako Nagasaka

Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer

Bob T. Li, Egbert F. Smit, Yasushi Goto et al. · New England Journal of Medicine · 2021 · 886 citations · Full text

Repotrectinib in <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer

Alexander Drilon, D. Ross Camidge, Sang‐We Kim et al. · New England Journal of Medicine · 2024 · 178 citations · Full text

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

Jessica Lee, Smruthy Sivakumar, Alexa B. Schrock et al. · npj Precision Oncology · 2022 · 140 citations · Full text

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

Egbert F. Smit, Enriqueta Felip, Dipesh Uprety et al. · The Lancet Oncology · 2024 · 123 citations · Full text

Oncology, Primary Results, Her2-overexpressing Cohorts +9

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.

Egbert F. Smit, Kazuhiko Nakagawa, Misako Nagasaka et al. · Journal of Clinical Oncology · 2020 · 118 citations

Immunology, Pathology, Data Cutoff +20